BCIQ Profiles

Company Profile Report
0914 Quick Takes Finance
BioCentury & Getty Images


Sept. 14 Quick Takes: Out of stealth, Vanqua gets $85M series B

Plus: venture cash for Skyhawk, Rome, Treefrog, Alebund and more

Sep 15, 2021 | 1:45 AM GMT

Neurodegeneration company Vanqua Bio expects to bring a GBA activator program into the clinic with a new $85 million series B round, revealed Tuesday as the company officially launched. Led by co-founder and CEO Jim Sullivan, who is also a venture partner with series A investor OrbiMed Advisors, Vanqua hopes to advance its therapies initially to treat Gaucher disease and Parkinson’s

Read the full 921 word article

How to gain access

Continue reading with a
two-week free trial.